Head to Head Comparison: Oncobiologics (ONS) versus Enanta Pharmaceuticals (ENTA)

Oncobiologics (NYSE: ONS) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap biotechnology & medical research – nec companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Institutional and Insider Ownership

66.3% of Enanta Pharmaceuticals shares are held by institutional investors. 9.3% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Oncobiologics and Enanta Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Oncobiologics N/A N/A N/A ($1.84) -0.68
Enanta Pharmaceuticals $88.27 million 10.37 $21.66 million ($1.07) -44.83

Enanta Pharmaceuticals has higher revenue and earnings than Oncobiologics. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.


This table compares Oncobiologics and Enanta Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oncobiologics -1,757.25% N/A -123.55%
Enanta Pharmaceuticals -51.85% -7.74% -7.39%

Analyst Ratings

This is a summary of recent recommendations and price targets for Oncobiologics and Enanta Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncobiologics 0 1 1 0 2.50
Enanta Pharmaceuticals 0 1 3 0 2.75

Oncobiologics presently has a consensus target price of $9.00, suggesting a potential upside of 620.00%. Enanta Pharmaceuticals has a consensus target price of $45.25, suggesting a potential downside of 5.67%. Given Oncobiologics’ higher possible upside, equities research analysts plainly believe Oncobiologics is more favorable than Enanta Pharmaceuticals.


Enanta Pharmaceuticals beats Oncobiologics on 8 of the 10 factors compared between the two stocks.

Oncobiologics Company Profile

Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company’s other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab (Erbitux).

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.

Receive News & Ratings for Oncobiologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply